May CTC technologies promote better cancer management?

Area of Science:

• Oncology
• Translational Medicine
• Cancer Diagnostics

Background:

• Cancer mortality is primarily driven by metastasis, not the primary tumor.
• Circulating tumor cells (CTCs) are key players in metastasis formation.
• Analysis of CTCs holds promise for advancing predictive, preventive, and personalized medicine (PPPM) in oncology.

Purpose of the Study:

• To identify key limitations hindering the clinical utility of circulating tumor cell (CTC) analysis.
• To highlight areas where CTCs can be effectively integrated into clinical practice for improved cancer management.
• To underscore the importance of addressing biological and interdisciplinary challenges in CTC diagnostics.

Main Methods:

• Review of current challenges in CTC analysis for clinical application.
• Discussion of biological factors influencing CTC diagnostics.
• Exploration of the interdisciplinary nature of CTC diagnostics (pathology, hematology, biochemistry).

Main Results:

• Two primary reasons limit the current diagnostic value of CTC analysis: inherent tumor biology and the interdisciplinary nature of CTC diagnostics.
• Despite limitations, CTCs show potential in three key clinical areas: monitoring treatment efficacy, molecular characterization for targeted therapy, and drug sensitivity testing via cultivation.

Conclusions:

• Overcoming biological and interdisciplinary hurdles is crucial for integrating CTC analysis into routine clinical practice.
• CTCs offer significant potential for personalized cancer care through treatment monitoring, targeted therapy selection, and drug sensitivity assays.
• The integration of CTC analysis supports the goals of predictive, preventive, and personalized medicine (PPPM) by enabling dynamic patient management.